June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Oral teriflunomide effect on visual function in multiple sclerosis: multifocal electroretinogram responses after 12 months of treatment.
Author Affiliations & Notes
  • Anna Camos-Carreras
    Ophthalmology Department, Hospital Clinic de Barcelona, Barcelona, Catalunya, Spain
  • Marc Figueras-Roca
    Ophthalmology Department, Hospital Clinic de Barcelona, Barcelona, Catalunya, Spain
  • Marina Dotti-Boada
    Ophthalmology Department, Hospital Clinic de Barcelona, Barcelona, Catalunya, Spain
  • Salut Alba-Arbalat
    Neurology Department, Hospital Clinic de Barcelona, Barcelona, Catalunya, Spain
  • Sara Llufriu
    Neurology Department, Hospital Clinic de Barcelona, Barcelona, Catalunya, Spain
  • Albert Saiz
    Neurology Department, Hospital Clinic de Barcelona, Barcelona, Catalunya, Spain
  • Pablo Villoslada
    Neurology Department, Hospital Clinic de Barcelona, Barcelona, Catalunya, Spain
  • Bernardo Sanchez-Dalmau
    Ophthalmology Department, Hospital Clinic de Barcelona, Barcelona, Catalunya, Spain
  • Footnotes
    Commercial Relationships   Anna Camos-Carreras None; Marc Figueras-Roca None; Marina Dotti-Boada None; Salut Alba-Arbalat None; Sara Llufriu Biogen Idec, Novartis, TEVA, Genzyme, Sanofi and Merck, Code C (Consultant/Contractor); Albert Saiz Bayer-Schering, Merck-Serono, Biogen-Idec, Sanofi-Aventis, TEVA, Novartis and Roche, Code C (Consultant/Contractor); Pablo Villoslada None; Bernardo Sanchez-Dalmau hiesi and Sanofi-Genzyme, Code C (Consultant/Contractor)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 755 – F0407. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Anna Camos-Carreras, Marc Figueras-Roca, Marina Dotti-Boada, Salut Alba-Arbalat, Sara Llufriu, Albert Saiz, Pablo Villoslada, Bernardo Sanchez-Dalmau; Oral teriflunomide effect on visual function in multiple sclerosis: multifocal electroretinogram responses after 12 months of treatment.. Invest. Ophthalmol. Vis. Sci. 2022;63(7):755 – F0407.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Development of predictive biomarkers of response to therapy is a priority for therapeutic optimization in multiple sclerosis (MS). The retina represents an ideal model to investigate effects of disease modifying therapies (DMTs) using non-invasive technologies such as multifocal electroretinography (mfERG) and optical coherence tomography (SD-OCT). After DMTs onset, functional changes may precede structural ones, so neurophysiological retinal response deserves further evaluation. The aim of this study was to analyze changes of first kernel mfERG responses after 12 months of oral teriflunomide treatment (14mg/day) in patients with relapsing-remitting MS (RRMS).

Methods : We conducted a prospective open-label study in RRMS patients starting treatment with oral teriflunomide. Patients were assessed at baseline and after 12 months of follow-up. Baseline exploration consisted of monocular 2.5% low contrast letter acuity (2.5% LCLA), SD-OCT (Spectralis, Heidelberg), mfERG (Reti-Port Science, Roland Consult) and Expanded Disability Status Scale (EDSS). At 12 months of teriflunomide treatment, mfERG exam was repeated. mfERG first kernel responses included N1 wave amplitude and peak time as well as P1 wave amplitude and peak time; results were provided as mfERG sum response and sectorial responses by concentric rings (1-5).

Results : 24 subjects (75% females; mean age of 46.8 years), mild disabled (median EDSS=2.0), were included by March 2018 and completed one year of follow-up. mfERG first kernel responses changed over 12 months showing a mean amplitude increase in N1 (+1.19 nV/deg2 [+17.4%], p=0.048) and P1 (+3.55 nV/deg2 [+20.4%], p=0.006) as well as a decreased peak time in N1 wave (-0.002 ms [-6.7%], p=0.006). Considering sectorial (ring) responses, significant increases were found in N1 amplitude (ring 5) and decreases in peak time (ring 1, ring 3 and ring 4) as well as increases in P1 amplitude (ring 3, ring 4 and ring 5).

Conclusions : After 12 months of teriflunomide oral treatment in RRMS patients, we observed significant improvement in retinal function, as revealed by increased wave amplitudes as well as decreased latencies. Considering lack of a control group, the small sample size and the variability of mfERG explorations, these results require further confirmation.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

 

Significant results marked with (*).

Significant results marked with (*).

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×